Matthew Foehr Sells 30,843 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew Foehr sold 30,843 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.71, for a total transaction of $52,741.53. Following the completion of the transaction, the chief executive officer owned 4,403,277 shares of the company’s stock, valued at approximately $7,529,603.67. The trade was a 0.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

OmniAb Stock Performance

Shares of NASDAQ:OABI remained flat at $1.71 during mid-day trading on Wednesday. 342,206 shares of the company traded hands, compared to its average volume of 375,697. The stock has a market capitalization of $246.17 million, a P/E ratio of -2.95 and a beta of 0.13. OmniAb, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $4.02. The firm’s 50-day simple moving average is $1.89 and its 200 day simple moving average is $1.76.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OmniAb in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.67.

Key OmniAb News

Here are the key news stories impacting OmniAb this week:

• Positive Sentiment: Institutional buying and concentrated ownership: several funds (Osaic, AQR, BNP Paribas, Cerity Partners, SG Americas) have recently increased or established stakes; institutional ownership is reported above 70%, which can support liquidity and longer-term stability. MarketBeat OABI page
• Neutral Sentiment: Analyst coverage is mixed: MarketBeat shows an average “Moderate Buy” rating and a mean price target near $6.67, but Weiss Ratings has a “sell (e+)” on the stock — a signal of divergent views that can keep trading range-bound. MarketBeat OABI page
• Neutral Sentiment: Key trading metrics: shares are being reported around $1.71 with a 50-day moving average (~$1.89) and 200-day (~$1.76); negative trailing P/E reflects current losses. These metrics frame risk/reward but do not convey near-term directional catalysts. MarketBeat OABI page
• Negative Sentiment: CEO Matthew W. Foehr sold shares on Feb. 17–18 (totaling 51,597 shares across two filings), reducing his stake modestly; filings: Feb. 18 sale. CEO Feb 18 Form 4 and Feb. 17 sale. CEO Feb 17 Form 4
• Negative Sentiment: CFO Kurt A. Gustafson sold shares on Feb. 17–18 (totaling 16,129 shares across two filings), trimming his holding by a few percent; filings: Feb. 18. CFO Feb 18 Form 4 and Feb. 17. CFO Feb 17 Form 4
• Negative Sentiment: Director Charles S. Berkman sold shares on Feb. 17–18 (totaling 16,663 shares across two filings), reducing his stake by a few percent; filings: Feb. 18. Director Feb 18 Form 4 and Feb. 17. Director Feb 17 Form 4

Institutional Trading of OmniAb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in shares of OmniAb during the first quarter valued at about $25,000. Jane Street Group LLC increased its stake in OmniAb by 26.3% during the first quarter. Jane Street Group LLC now owns 80,778 shares of the company’s stock valued at $194,000 after acquiring an additional 16,823 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in OmniAb in the 2nd quarter valued at approximately $79,000. Connors Investor Services Inc. grew its holdings in shares of OmniAb by 25.0% during the 2nd quarter. Connors Investor Services Inc. now owns 62,000 shares of the company’s stock worth $108,000 after purchasing an additional 12,389 shares in the last quarter. Finally, Towerview LLC increased its position in shares of OmniAb by 43.3% during the second quarter. Towerview LLC now owns 831,100 shares of the company’s stock valued at $1,446,000 after purchasing an additional 251,100 shares during the period. 72.08% of the stock is currently owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.